ACAD | ACADIA Pharmaceuticals Inc. | [NASD]
Index- P/E- EPS (ttm)-0.90 Insider Own0.10% Shs Outstand162.26M Perf Week1.93%
Market Cap3.98B Forward P/E- EPS next Y-0.01 Insider Trans- Shs Float161.70M Perf Month20.88%
Income-145.90M PEG- EPS next Q-0.19 Inst Own94.90% Short Float / Ratio6.17% / 5.96 Perf Quarter27.73%
Sales520.20M P/S7.64 EPS this Y-27.70% Inst Trans0.94% Short Interest9.97M Perf Half Y65.20%
Book/sh2.31 P/B10.73 EPS next Y100.00% ROA-23.70% Target Price23.16 Perf Year55.07%
Cash/sh2.51 P/C9.87 EPS next 5Y25.00% ROE-35.70% 52W Range12.24 - 26.04 Perf YTD55.65%
Dividend- P/FCF- EPS past 5Y5.80% ROI-56.50% 52W High-4.84% Beta0.52
Dividend %- Quick Ratio2.20 Sales past 5Y32.90% Gross Margin98.30% 52W Low102.45% ATR0.82
Employees540 Current Ratio2.20 Sales Q/Q2.60% Oper. Margin-31.50% RSI (14)69.05 Volatility4.14% 3.69%
OptionableYes Debt/Eq0.00 EPS Q/Q62.20% Profit Margin-28.10% Rel Volume0.62 Prev Close24.45
ShortableYes LT Debt/Eq0.00 EarningsMay 08 AMC Payout- Avg Volume1.67M Price24.78
Recom2.60 SMA209.84% SMA5020.94% SMA20038.16% Volume1,044,076 Change1.35%
Date Action Analyst Rating Change Price Target Change
Jan-03-23Upgrade Guggenheim Neutral → Buy $22
Nov-04-22Downgrade Goldman Neutral → Sell $15 → $12
Nov-01-22Initiated Loop Capital Hold $17
Aug-08-22Downgrade Citigroup Buy → Neutral $19 → $15
Aug-05-22Downgrade Citigroup Buy → Neutral $19 → $15
Jun-21-22Downgrade Jefferies Buy → Underperform $25 → $10
Jun-16-22Upgrade Jefferies Hold → Buy $25
Mar-16-22Upgrade Canaccord Genuity Hold → Buy $30 → $31
Feb-09-22Upgrade H.C. Wainwright Neutral → Buy $36
Jan-05-22Upgrade Citigroup Neutral → Buy $30
May-08-23 05:25PM
May-05-23 04:04PM
May-02-23 09:04AM
09:04AM Loading…
Apr-25-23 09:04AM
Apr-20-23 09:04AM
Apr-17-23 09:04AM
Apr-11-23 09:04AM
Mar-13-23 12:56PM
Mar-10-23 09:45PM
Mar-07-23 09:45AM
Mar-02-23 05:45AM
05:41AM Loading…
Mar-01-23 05:41AM
Feb-28-23 04:00PM
Feb-27-23 05:25PM
Feb-20-23 10:00AM
Feb-14-23 04:05PM
Feb-13-23 04:15PM
Jan-09-23 09:00AM
Jan-03-23 11:58AM
Dec-21-22 04:05PM
Nov-08-22 04:05PM
Nov-03-22 12:23PM
05:35PM Loading…
Nov-02-22 05:35PM
Nov-01-22 10:04AM
Oct-27-22 04:05PM
Oct-26-22 10:02AM
Oct-20-22 04:05PM
Oct-19-22 12:02PM
Oct-13-22 07:30AM
Oct-12-22 10:57AM
Oct-06-22 01:36PM
Oct-04-22 02:19PM
Sep-13-22 08:44AM
Sep-12-22 07:30AM
Sep-07-22 11:30AM
Sep-01-22 09:03AM
Aug-30-22 09:55AM
Aug-26-22 12:00PM
Aug-09-22 01:24PM
Aug-08-22 05:35PM
Aug-05-22 07:55AM
Aug-04-22 11:39PM
Aug-01-22 10:01AM
Jul-27-22 08:23AM
Jul-25-22 04:05PM
Jul-19-22 11:22AM
Jul-18-22 04:07PM
Jul-08-22 11:14AM
Jun-21-22 12:07PM
Jun-17-22 08:00PM
Jun-16-22 03:42PM
Jun-15-22 04:53PM
Jun-03-22 11:31AM
May-19-22 09:01AM
May-05-22 10:06AM
May-04-22 06:15PM
May-03-22 04:05PM
May-02-22 04:05PM
Apr-27-22 03:03PM
Apr-21-22 09:09AM
Apr-19-22 05:52PM
Apr-18-22 04:05PM
Mar-30-22 11:30AM
Mar-25-22 02:26PM
Mar-22-22 09:00AM
Mar-10-22 04:05PM
Mar-09-22 08:30AM
Mar-03-22 09:00AM
Mar-01-22 09:43AM
Feb-28-22 05:35PM
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorMay 24Buy25.48553,26314,096,82539,317,673May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 23Option Exercise17.0125,000425,25038,620,261May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 23Buy25.41209,0535,312,45838,811,515May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 22Buy24.57134,2063,297,81538,607,761May 24 05:09 PM
Schneyer Mark C.EVP, Chief Financial OfficerMay 17Sale22.5015,310344,47521,905May 19 06:48 PM
Teehan BrendanEVP, COO, Head of CommercialMay 17Sale22.5014,869334,55224,356May 19 06:43 PM
Kihara JamesPrincipal Accounting OfficerMay 17Sale22.505,947133,80811,144May 19 06:54 PM
DAVIS STEPHENCEOMay 01Sale21.187,806165,331108,297May 02 07:02 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryMay 01Sale21.1891719,42225,513May 02 07:06 PM
Teehan BrendanEVP, COO, Head of CommercialMay 01Sale21.1854811,6079,487May 02 07:04 PM
Teehan BrendanEVP, COO, Head of CommercialApr 29Option Exercise0.001,567010,035May 02 07:04 PM
DAVIS STEPHENCEOApr 29Option Exercise0.0015,6250116,103May 02 07:02 PM
Kihara JamesPrincipal Accounting OfficerApr 10Sale18.145239,4875,197Apr 11 09:15 PM
DAVIS STEPHENCEOApr 06Sale18.168,582155,849100,478Apr 07 08:34 PM
Schneyer Mark C.EVP, Chief Financial OfficerApr 06Sale18.161,91634,7957,477Apr 07 08:37 PM
Teehan BrendanEVP, COO, Head of CommercialApr 06Sale18.161,75131,7988,468Apr 07 08:44 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryApr 06Sale18.161,45626,44123,425Apr 07 08:32 PM
Kihara JamesPrincipal Accounting OfficerApr 06Sale18.1670112,7304,231Apr 07 08:41 PM
DAVIS STEPHENCEOFeb 24Sale18.783,85172,32291,727Feb 27 09:00 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryFeb 24Sale18.7880315,08020,108Feb 27 09:00 PM
Schneyer Mark C.EVP, Chief Financial OfficerFeb 24Sale18.7857710,8364,118Feb 27 09:00 PM
Teehan BrendanEVP, COO, Head of CommercialFeb 24Sale18.784618,6585,195Feb 27 09:00 PM
Kihara JamesPrincipal Accounting OfficerFeb 24Sale18.783506,5732,923Feb 27 09:00 PM
Brege LauraDirectorJan 12Option Exercise17.0112,500212,62512,500Jan 17 05:17 PM
BAKER BROS. ADVISORS LPDirectorJan 12Option Exercise5.2230,000156,60038,484,981Jan 17 04:22 PM
Brege LauraDirectorJan 12Sale18.2512,500228,1250Jan 17 05:17 PM
DAVIS STEPHENCEOJan 09Sale17.133,90466,87784,633Jan 10 08:38 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryJan 09Sale17.1358910,09018,697Jan 10 08:20 PM
Teehan BrendanEVP, COO, Head of CommercialJan 09Sale17.135329,1134,549Jan 10 08:30 PM
Stankovic Srdjan R.PresidentNov 21Sale15.071,84727,83461,234Nov 22 04:34 PM
DAVIS STEPHENCEOOct 15Sale15.812,80444,33179,009Oct 18 09:16 PM
Stankovic Srdjan R.PresidentOct 15Sale15.811,32620,96456,831Oct 18 09:22 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 09Sale17.9165311,6953,342Jun 10 08:51 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Option Exercise0.001,89303,995Jun 10 08:51 PM